Menu
Back to Journals » Psoriasis: Targets and Therapy
Psoriasis: Targets and Therapy
ISSN: 2230-326X
- View all (129)
- Volume 13, 2023 (3)
- Volume 12, 2022 (22)
- Volume 11, 2021 (14)
- Volume 10, 2020 (8)
- Volume 9, 2019 (13)
- Volume 8, 2018 (12)
- Volume 7, 2017 (9)
- Volume 6, 2016 (15)
- Volume 5, 2015 (13)
- Volume 4, 2014 (5)
- Volume 3, 2013 (4)
- Volume 2, 2012 (10)
- Volume 1, 2011 (1)
Journal Articles:
- 129 records -
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
Potestio L, Ruggiero A, Fabbrocini G, Martora F, Megna M
Psoriasis: Targets and Therapy 2023, 13:19-26
Published Date: 4 May 2023
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
Potestio L, Martora F, Fabbrocini G, Battista T, Megna M
Psoriasis: Targets and Therapy 2023, 13:11-18
Published Date: 12 April 2023
Analysis of Drug Utilization in Patients with Psoriasis: A Real-World Retrospective Study Among the Italian Population
Perrone V, Losi S, Sabatino S, Mezzetti M, Dovizio M, Sangiorgi D, Degli Esposti L
Psoriasis: Targets and Therapy 2023, 13:1-9
Published Date: 2 March 2023
Assessment of Vitamin D Level in Patients with Psoriasis and Its Correlation with Disease Severity: A Case–Control Study
Pokharel R, Agrawal S, Pandey P, Lamsal M
Psoriasis: Targets and Therapy 2022, 12:251-258
Published Date: 13 September 2022
Towards Personalized Medicine in Psoriasis: Current Progress
Camela E, Potestio L, Ruggiero A, Ocampo-Garza SS, Fabbrocini G, Megna M
Psoriasis: Targets and Therapy 2022, 12:231-250
Published Date: 1 September 2022
Therapeutic Inertia in the Management of Psoriasis: A Quantitative Survey Among Indian Dermatologists and Patients
Rajagopalan M, Dogra S, Godse K, Kar BR, Kotla SK, Neema S, Saraswat A, Shah SD, Madnani N, Sardesai V, Sekhri R, Varma S, Arora S, Kawatra P
Psoriasis: Targets and Therapy 2022, 12:221-230
Published Date: 25 August 2022
Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis
Gisondi P, Bellinato F, Maurelli M, Geat D, Zabotti A, McGonagle D, Girolomoni G
Psoriasis: Targets and Therapy 2022, 12:213-220
Published Date: 10 August 2022
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
Megna M, Potestio L, Fabbrocini G, Ruggiero A
Psoriasis: Targets and Therapy 2022, 12:205-212
Published Date: 14 July 2022
Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study
Megna M, Fornaro L, Potestio L, Luciano MA, Nocerino M, Delfino M, Guarino M, Fabbrocini G, Camela E
Psoriasis: Targets and Therapy 2022, 12:199-204
Published Date: 9 July 2022
Psoriasis and Exercise: A Review
Yeroushalmi S, Hakimi M, Chung M, Bartholomew E, Bhutani T, Liao W
Psoriasis: Targets and Therapy 2022, 12:189-197
Published Date: 2 July 2022
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management [Corrigendum]
Al-Janabi A, Yiu ZZN
Psoriasis: Targets and Therapy 2022, 12:187-188
Published Date: 1 July 2022
Dimethyl Fumarate as Therapeutic Alternative in Moderate-to-Severe Psoriasis: Our Experience
Rosés Gibert P, de la Torre Gomar FJ, Saenz Aguirre A, Gimeno Castillo J, González Pérez R
Psoriasis: Targets and Therapy 2022, 12:177-185
Published Date: 29 June 2022
Dietary Intervention and Supplements in the Management of Psoriasis: Current Perspectives
Chung M, Bartholomew E, Yeroushalmi S, Hakimi M, Bhutani T, Liao W
Psoriasis: Targets and Therapy 2022, 12:151-176
Published Date: 22 June 2022
Comorbidity in Adult Psoriasis: Considerations for the Clinician
Daugaard C, Iversen L, Hjuler KF
Psoriasis: Targets and Therapy 2022, 12:139-150
Published Date: 10 June 2022
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M
Psoriasis: Targets and Therapy 2022, 12:127-137
Published Date: 8 June 2022
Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management
De Brandt E, Hillary T
Psoriasis: Targets and Therapy 2022, 12:113-126
Published Date: 25 May 2022
Biologics Can Significantly Improve Dermatology Life Quality Index (DLQI) in Psoriatic Patients: A Systematic Review
de Ruiter CC, Rustemeyer T
Psoriasis: Targets and Therapy 2022, 12:99-112
Published Date: 24 May 2022
Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study
Löfvendahl S, Norlin JM, Schmitt-Egenolf M
Psoriasis: Targets and Therapy 2022, 12:89-98
Published Date: 5 May 2022
Updated Perspectives on Keratinocytes and Psoriasis: Keratinocytes are More Than Innocent Bystanders
Ortiz-Lopez LI, Choudhary V, Bollag WB
Psoriasis: Targets and Therapy 2022, 12:73-87
Published Date: 2 May 2022
The Efficacy and Tolerability of Turmeric and Salicylic Acid in Psoriasis Treatment
Draelos ZD
Psoriasis: Targets and Therapy 2022, 12:63-71
Published Date: 29 April 2022
An Open-Label, Randomized, Prospective, Comparative, Three-Arm Clinical Trial to Evaluate the Safety and Effectiveness of Apremilast with Three Different Titration Methods in Patients with Chronic Plaque Psoriasis in India
Viswanath V, Joshi P, Lawate P, Tare D, Dhoot D, Mahadkar N, Barkate H
Psoriasis: Targets and Therapy 2022, 12:53-61
Published Date: 22 April 2022
The Effect of Lifestyle Changes on Disease Severity and Quality of Life in Patients with Plaque Psoriasis: A Narrative Review
van Acht MR, van den Reek JMPA, de Jong EMGJ, Seyger MMB
Psoriasis: Targets and Therapy 2022, 12:35-51
Published Date: 9 April 2022
Assessing and Improving Psychological Well-Being in Psoriasis: Considerations for the Clinician
Blackstone B, Patel R, Bewley A
Psoriasis: Targets and Therapy 2022, 12:25-33
Published Date: 25 March 2022
Telemedicine and e-Health in the Management of Psoriasis: Improving Patient Outcomes – A Narrative Review
Havelin A, Hampton P
Psoriasis: Targets and Therapy 2022, 12:15-24
Published Date: 16 March 2022
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
Al-Janabi A, Yiu ZZN
Psoriasis: Targets and Therapy 2022, 12:1-14
Published Date: 6 January 2022
The Use of Metrics in Daily Practice and the Perception of Psoriasis-Associated Comorbidities: Discrepancies Between Research and Real-World
Hillary T, Lambert J
Psoriasis: Targets and Therapy 2021, 11:169-175
Published Date: 21 December 2021
Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies
Balak DMW, Piaserico S, Kasujee I
Psoriasis: Targets and Therapy 2021, 11:151-168
Published Date: 7 December 2021
High-Throughput RNA Sequencing Reveals the Effect of NB-UVB Phototherapy on Major Inflammatory Molecules of Lesional Psoriasis
Vacharanukrauh P, Meephansan J, Tangtanatakul P, Soonthornchai W, Wongpiyabovorn J, Serirat O, Komine M
Psoriasis: Targets and Therapy 2021, 11:133-149
Published Date: 26 November 2021
Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
Hampton P, Borg E, Hansen JB, Augustin M
Psoriasis: Targets and Therapy 2021, 11:123-131
Published Date: 3 November 2021
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
Rajagopalan M, Dogra S, Saraswat A, Varma S, Banodkar P
Psoriasis: Targets and Therapy 2021, 11:109-122
Published Date: 14 August 2021
Psoriasis and Cardiometabolic Diseases: The Impact of Inflammation on Vascular Health
Teklu M, Parel PM, Mehta NN
Psoriasis: Targets and Therapy 2021, 11:99-108
Published Date: 21 July 2021
Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics
Ben Abdallah H, Johansen C, Iversen L
Psoriasis: Targets and Therapy 2021, 11:83-97
Published Date: 29 June 2021
An Association of Pediatric Psoriasis with Metabolic Syndrome in Thai Children: 20 Years Retrospective Study
Mhusakunchai P, Techasatian L
Psoriasis: Targets and Therapy 2021, 11:75-82
Published Date: 29 June 2021
Updates on the Treatment of Erythrodermic Psoriasis
Lo Y, Tsai TF
Psoriasis: Targets and Therapy 2021, 11:59-73
Published Date: 9 June 2021
Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
Chan Y, Tong BSB, Ngan PY, Au CS
Psoriasis: Targets and Therapy 2021, 11:53-58
Published Date: 1 June 2021
Association of HLA Alleles and HLA Haplotypes with Psoriasis, Psoriatic Arthritis and Disease Severity in a Miscegenated Population
Cassia FF, Cardoso JF, Porto LC, Ramos-e-Silva M, Carneiro S
Psoriasis: Targets and Therapy 2021, 11:41-51
Published Date: 10 May 2021
Frequency of Health Care Resource Utilization and Direct Medical Costs Associated with Psoriatic Arthritis in a Rheumatic Care Center in Colombia
Santos-Moreno P, Gómez-De la Rosa F, Parra-Padilla D, Alvis-Zakzuk NJ, Alvis-Zakzuk NR, Carrasquilla-Sotomayor M, Valencia O, Alvis-Guzmán N
Psoriasis: Targets and Therapy 2021, 11:31-39
Published Date: 18 March 2021
Phosphodiesterase-4 Inhibition in Psoriasis
Milakovic M, Gooderham MJ
Psoriasis: Targets and Therapy 2021, 11:21-29
Published Date: 17 March 2021
Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic
Haulrig MB, Zachariae C, Skov L
Psoriasis: Targets and Therapy 2021, 11:1-20
Published Date: 11 February 2021
A Successful Treatment of Ostraceous Psoriasis Associated with Psoriatic Arthritis in Children: A Case Report
Rowawi R, Dwipangestu G, Suwarsa O, Dharmadji HP, Sutedja E, Pangastuti M, Gunawan H
Psoriasis: Targets and Therapy 2020, 10:61-66
Published Date: 30 December 2020
CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab
Gambardella A, Licata G, Calabrese G, De Rosa A, Pagliuca F, Alfano R, Argenziano G
Psoriasis: Targets and Therapy 2020, 10:57-60
Published Date: 27 November 2020
Optimal Management of Plaque Psoriasis in Adolescents: Current Perspectives
Mahé E
Psoriasis: Targets and Therapy 2020, 10:45-56
Published Date: 27 November 2020
Correlation Between Psoriasis Severity and Nonalcoholic Fatty Liver Disease Degree Measured Using Controlled Attenuation Parameter
Gandha N, Wibawa LP, Jacoeb TNA, Sulaiman AS
Psoriasis: Targets and Therapy 2020, 10:39-44
Published Date: 20 October 2020
The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy
van Muijen ME, van Hal TW, Groenewoud HMM, van den Reek JMPA, de Jong EMGJ
Psoriasis: Targets and Therapy 2020, 10:29-37
Published Date: 5 October 2020
The Unmet Need for Clinical Guidelines on the Management of Patients with Plaque Psoriasis in Africa and the Middle East
Steinhoff M, Ammoury AF, Ahmed HM, Gamal MFS, El Sayed MH
Psoriasis: Targets and Therapy 2020, 10:23-28
Published Date: 20 August 2020
Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
Anani HAA, Tawfeik AM, Maklad SS, Kamel AM, El-Said EE, Farag AS
Psoriasis: Targets and Therapy 2020, 10:13-21
Published Date: 21 May 2020
Dimethyl Fumarate Targets MSK1, RSK1, 2 and IKKα/β Kinases and Regulates NF-κB /p65 Activation in Psoriasis: A Demonstration of the Effect on Peripheral Blood Mononuclear Cells, Drawn from Two Patients with Severe Psoriasis Before and After Treatment with Dimethyl Fumarate
Gesser B, Rasmussen MK, Iversen L
Psoriasis: Targets and Therapy 2020, 10:1-11
Published Date: 31 March 2020
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
Ly K, Beck KM, Smith MP, Orbai AM, Liao W
Psoriasis: Targets and Therapy 2019, 9:97-107
Published Date: 28 August 2019
Psoriasis and uveitis: links and risks
Fotiadou C, Lazaridou E
Psoriasis: Targets and Therapy 2019, 9:91-96
Published Date: 28 August 2019
A narrative review of psoriasis and multiple sclerosis: links and risks
Silfvast-Kaiser AS, Homan KB, Mansouri B
Psoriasis: Targets and Therapy 2019, 9:81-90
Published Date: 22 August 2019